SetmelanotideMeSH Supplementary Concept

https://ansm.sante.fr/tableau-acces-derogatoire/imcivree#
2025
false
false
false
France
French
setmelanotide
adult
adolescent
child
obesity
obesity
bardet-biedl syndrome
continuity of patient care
drug monitoring
product surveillance, postmarketing
setmelanotide
injections, subcutaneous
guidelines for drug use
package leaflet
summary of product characteristics
technical report

---
https://www.has-sante.fr/jcms/p_3421149/fr/imcivree-setmelanotide-syndrome-de-bardet-biedl-sbb
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
setmelanotide
setmelanotide
bardet-biedl syndrome
obesity
adult
child
adolescent
bardet-biedl syndrome
injections, subcutaneous
obesity due to Bardet-Biedl Syndrome

---
https://www.has-sante.fr/jcms/p_3416571/fr/imcivree-setmelanotide-pomc
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
anti-obesity agents
setmelanotide
adult
child
adolescent
obesity
proopiomelanocortin deficiency
Obesity due to leptin receptor gene deficiency
Prohormone Convertase 1 Deficiency
Leptin Receptor Deficiency
evaluation of the transparency committee
alpha-msh
setmelanotide

---
https://www.has-sante.fr/jcms/p_3456790/fr/imcivree-setmelanotide-obesite
2023
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
child
adolescent
obesity
receptor, melanocortin, type 4
Obesity due to melanocortin 4 receptor deficiency (disorder)
guidelines for drug use
hypothalamic diseases
setmelanotide
evaluation of the transparency committee
setmelanotide

---
https://www.has-sante.fr/jcms/p_3463613/fr/imcivree-setmelanotide-traitement-de-l-obesite-et-du-controle-de-la-faim-sbb
2023
false
false
false
France
bardet-biedl syndrome
insurance, health, reimbursement
adult
child
setmelanotide
obesity due to Bardet-Biedl Syndrome
receptor, melanocortin, type 4
evaluation of the transparency committee
setmelanotide
obesity
hunger

---
https://www.has-sante.fr/jcms/p_3352501/fr/imcivree-setmelanotide-obesite
https://www.has-sante.fr/jcms/p_3352529/fr/decision-n2022-0238/dc/sem-du-7-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-imcivree
2022
false
false
false
France
bardet-biedl syndrome
treatment outcome
insurance, health, reimbursement
setmelanotide
adult
child
adolescent
injections, subcutaneous
bardet-biedl syndrome
anti-obesity agents
evaluation of the transparency committee
obesity
setmelanotide

---
https://www.has-sante.fr/jcms/p_3324540/fr/imcivree-setmelanotide
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
adult
child
adolescent
obesity
anti-obesity agents
proopiomelanocortin deficiency
Obesity due to leptin receptor gene deficiency
setmelanotide
evaluation of the transparency committee
setmelanotide
imcivree

---
https://www.has-sante.fr/jcms/p_3310631/fr/imcivree-setmelanotide
https://www.has-sante.fr/jcms/p_3310638/fr/decision-n-2022-0026/dc/sem-du-19-janvier-2022-de-la-presidente-de-la-haute-autorite-de-sante-prise-au-nom-du-college-portant-autorisation-d-acces-precoce-de-la-specialite-imcivree
2022
false
false
false
France
treatment outcome
adult
child
adolescent
obesity
obesity
proopiomelanocortin deficiency
anti-obesity agents
Obesity due to leptin receptor gene deficiency
receptors, leptin
PCSK1 protein, human
guidelines for drug use
data collection
continuity of patient care
mutation
rare diseases
injections, subcutaneous
setmelanotide
evaluation of the transparency committee

---
https://www.has-sante.fr/jcms/p_3403261/fr/imcivree-setmelanotide-obesite
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
child
adolescent
adult
setmelanotide
proopiomelanocortin deficiency
proopiomelanocortin deficiency
pro-opiomelanocortin
evaluation of the transparency committee
imcivree
setmelanotide
obesity

---
https://www.ema.europa.eu/en/medicines/human/EPAR/imcivree
2021
false
false
false
Netherlands
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
centrally acting antiobesity products
anti-obesity agents
anti-obesity agents
adult
child
adolescent
Obesity due to leptin receptor gene deficiency
obesity
obesity
Obesity due to pro-opiomelanocortin deficiency
orphan drug production
pro-opiomelanocortin
Pro-Opiomelanocortin Deficiency
Leptin Receptor Deficiency
receptors, leptin
injections, subcutaneous
drug monitoring
pregnancy
breast feeding
receptor, melanocortin, type 4
drug evaluation, preclinical
proopiomelanocortin deficiency
setmelanotide
setmelanotide
alpha-msh
alpha-msh
alpha-msh

---